ESMO 2021 | EPIK-P1 study: alpelisib for PIK3CA-related overgrowth spectrum disorders

Guillaume Canaud, MD, PhD, Université de Paris, Paris, France, gives an overview of PIK3CA-related overgrowth spectrum (PROS) and of the EPIK-P1 clinical trial (NCT04285723). PROS is a condition caused by PIK3CA gain-of-function mutations and associated with vascular anomalies. The EPIK-P1 study has evaluated the efficacy and safety of alpelisib, a PI3Kα inhibitor, for the first time in 57 patients. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.